Podcasts
Displaying 1–10 of 42
-
Eye on the Cure Podcast | Episode 72: Hannah Scanga
Eye on the CureHannah Scanga talks about the basics of genetic testing and counseling, and more.
-
Eye on the Cure Podcast | Episode 71: Dr. Leonide Saad
Eye on the CureDr. Saad discusses an emerging therapy for Stargardt disease that has performed well in clinical trials.
-
Eye on the Cure Podcast | Episode 70: Karen Petrou
Eye on the CureKaren Petrou, the new board chair at the Foundation, talks to host Ben Shaberman about her vision for the Foundation moving forward. Karen has been an active director on the Foundation’s board for nearly two decades. She is co-founder and managing partner of Federal Financial Analytics, a firm providing analytical and advisory services on legislative, regulatory, and public-policy issues affecting financial services companies. Karen has RP and lives in Washington, DC, with her guide dog, Ike.
-
Eye on the Cure Podcast | Episode 69: Dr. Francois Paquet-Durand
Eye on the CureFrancois Paquet-Durand, PhD, a professor from the University of Tübingen and co-founder of the company Mireca, talks to host Ben Shaberman about the long journey of an emerging, Foundation-funded drug for the treatment of certain forms of retinitis pigmentosa. The episode highlights the challenges that scientists often encounter when developing a drug for a retinal disease, and the persistence and tenacity that are required to keep it moving forward.
-
Eye on the Cure Podcast | Episode 68: Dr. Michael Telias
Eye on the CureFor this episode of Eye on the Cure, Michael Telias, PhD, an assistant professor at the University of Rochester in New York, talks with host Ben Shaberman about forthcoming clinical trials to evaluate the FDA-approved drug disulfiram (aka, Antabuse) for improving vision in people with retinitis pigmentosa and other retinal diseases. Disulfiram was originally developed to deter people from abusing alcohol.
-
Eye on the Cure Podcast | Episode 67: Dr. Peter Campochiaro
Eye on the CureDr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.
-
Eye on the Cure Podcast | Episode 66: Peter Wallsten
Eye on the CurePeter Wallsten, a veteran newspaper journalist and head of investigative reporting at The Washington Post, talks to host Ben Shaberman.
-
Eye on the Cure Podcast | Episode 65: Matthew Whitaker
Eye on the CureMatthew Whitaker talks to host Ben Shaberman about his remarkable achievements and success as a young jazz pianist and composer.
-
Eye on the Cure Podcast | Episode 64: Dr. Kapil Bharti
Eye on the CureKapil Bharti, PhD, a senior investigator and director of the Intramural Research Program at the National Eye Institute (NEI), talks with host Ben Shaberman about his clinical trial underway for an innovative cell therapy for geographic atrophy (advanced dry age-related macular degeneration) as well as a clinical trial of the drug metformin for Stargardt disease.
-
Eye on the Cure Podcast | Episode 63: Dr. Hema Ramkumar
Eye on the CureHema Ramkumar, MD, a retinal specialist, surgeon, and founder of the company Oculogenex, talks with host Ben Shaberman about her emerging therapy that targets mitchondria to slow the progression of intermediate dry age-related macular degeneration and potentially other retinal diseases. She also discusses her experiment that will put mice in space so researchers can gain a better understanding of retinal degeneration.
.png)
.png)
